156212-80-5

Basic information

• Product Name: 1H-Benzimidazole-2-carboxaldehyde,5-chloro-1-methyl-(9CI)
• Synonyms: 1H-Benzimidazole-2-carboxaldehyde,5-chloro-1-methyl-(9CI);5-chloro-1-methyl-1H-1,3-benzodiazole-2-carbaldehyde
• CAS NO: 156212-80-5
• Molecular Formula: C9H7ClN2O
• Molecular Weight: 194.62
• Product Categories: BENZIMIDAZOLE
• Mol File: 156212-80-5.mol

Chemical Properties

• Boiling Point: 367.7±34.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: 2.80±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-2-carboxaldehyde,5-chloro-1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-2-carboxaldehyde,5-chloro-1-methyl-(9CI)(156212-80-5)
• EPA Substance Registry System: 1H-Benzimidazole-2-carboxaldehyde,5-chloro-1-methyl-(9CI)(156212-80-5)

Safety Data

• Hazardous Substances Data: 156212-80-5(Hazardous Substances Data)

Usage

Class

Benzimidazoles (organic compounds)

Structure

Benzimidazole ring with a carboxaldehyde substituent at position 2, and a chlorine and a methyl group at position 5

Usage

Pharmaceutical and organic synthesis, production of pharmaceutical drugs and agrochemicals

Biological activities

Exhibits various biological activities suitable for use in pharmaceutical and agrochemical applications

Handling precautions

Potential hazards and reactivity, should be handled with care.

Upstream product

• 26960-04-3 5-chloro-1,2-dimethyl-1H-benzimidazole 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 6953-65-7 (5-chloro-1H-benzo [d]imidazol-2-yl)methanol 
• 380177-22-0 (N-methyl-5-chloro-1H-benzimidazole-2-yl)methanol 
• 2818-69-1 5-chloro-2-methyl-1H-benzimidazole 

Downstream Products

• 1357162-39-0 C₂₀H₁₇ClN₂O₃ 

Relevant articles and documents

Synthesis and antiprotozoal activity of novel 1-methylbenzimidazole derivatives

In this paper are reported the synthesis and antiprotozoal activity in vitro of 24 1-methylbenzimidazole derivatives (13-36) substituted at position 2 with aminocarbonyl, N-methylaminocarbonyl, N,N-dimethylaminocarbonyl, ethoxycarbonyl, 1-hydroxyethyl and acetyl groups, some of them with chlorine atoms at the benzenoid ring. Compounds 13-36 were more active than metronidazole, the choice drug against Giardia intestinalis and most of them against Trichomonas vaginalis. The most active group of compounds for both parasites was that with a 2-ethoxycarbonyl group (16, 22, 28, 34), independently of the substitution pattern at the benzenoid ring.

Synthesis of substituted benzimidazolyl curcumin mimics and their anticancer activity

A novel curcumin mimic library (14a-14h and 15a-15h) possessing variously substituted benzimidazole groups was synthesized through the aldol reaction of (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (7) or (E)-4-(3-hydroxy-4- methoxyphenyl)but-3-en-2-one (13) with diversely substituted benzimidazolyl-2-carbaldehyde (12a-12h). The MTT assay of the cancer cells MCF-7, SH-SY5Y, HEP-G2, and H460 showed that compound 14c with IC50 of 1.0 and 1.9 μM has a strong inhibitory effect on the growth of SH-SY5Y and Hep-G2 cells, respectively, and that compound 15h with IC50 of 1.9 μM has a strong inhibitory effect on the growth of MCF-7 cancer cells.

BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

Design and synthesis of 3-(benzimidazol-2-yl)-propionic acids as thromboxane A2 receptor antagonists

A series of 3-(benzimidazol-2-yl)-propionic acids substituted at the N1 nitrogen with methyl and benzyl groups and at the C5 and C6 positions with chloro, methoxy, amino, hydroxyl groups were synthesized and tested as TXA2 receptor antagonists.